• Nenhum resultado encontrado

Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer

N/A
N/A
Protected

Academic year: 2019

Share "Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer"

Copied!
7
0
0

Texto

Loading

Imagem

Figure 2 - Relative expression of KLK2 (A) and KLK3 (B) genes in pa- pa-tients according to their TNM (Tumor, lymph Node and Metastasis) tumor staging (pT1, pT2, pT3 and pT4) and benign prostatic hyperplasia (BPH) classification
Table 1 - Clinical parameters and laboratory data for expression analyses of the KLK2 and KLK3 genes in prostatic tissues and peripheral blood.
Table 2 - Calculation of clinical performance parameters of total serum prostate-specific antigen (tPSA) and the molecular markers KLK2 and KLK3 in peripheral blood and prostate tissues for prostate cancer diagnostics.

Referências

Documentos relacionados

Gene expression analysis of SSTR subtypes in primary prostate cancer tissues versus normal adjacent prostate tissues shows increased SSTR4 (p = 0.0236) and confirms lower

This meta-analysis suggests that the polymorphism rs198977 of KLK2 was associated with susceptibility of prostate cancer in Caucasian and the allele T might increase the risk

In this study, prostate cancer was located only in the anterior apex in 3 (3.2%) of the 95 patients who were diagnosed with prostate cancer by 6-core biopsy and 12 (25%) of the

Purpose: To retrospectively determine the accuracy of diffusion-weighted (DW) magnetic resonance (MR) imaging for identifying cancer in the prostate peripheral zone (PZ)

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart

To characterize the expression profile of androgen receptor target genes in prostate cancer cells, we used expression microarray analysis on the PC346 cell line panel incubated with

42 The presentation concluded that ADT is associated with an increased risk of CV events; however, the GnRH antagonist degarelix may be a promising drug, ofering increased

Silvers et al., “Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer,” The Prostate , vol.